Wed, Aug 27, 2014, 9:14 AM EDT - U.S. Markets open in 16 mins.


% | $
Quotes you view appear here for quick access.

Ironwood Pharmaceuticals, Inc. Message Board

rmsacc 307 posts  |  Last Activity: 15 hours ago Member since: Apr 24, 2012
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • "An illegal practice whereby two or more market makers collectively attempt to influence and change the price of a stock. Ghosting is used by corrupt companies to affect stock prices so they can profit from the price movement."

    An unfortunate result of market makers being given the ability to trade in the very stocks that they make markets for. You can thank the SEC for it............

  • rmsacc rmsacc Jun 13, 2014 11:06 AM Flag

    Well soon give the definitions to more manipulative tactics you guys use hedge, such as bear raiding, wash trading, runs, pools, etc.

    Will keep you posted....

  • Obviously avimoron, you are unaware of the long string of successes that Dr, Cauwenbergh has under his belt. Now with an even greater prospect with a "platform" technology allowing myriad partnering and licensing possibilities, I would say RXI's chances of success are very good.

    It appears that you do not know much about the company and its human elements, and your comments are merely generic.

    But hey, your a paid stock basher. You have only one agenda.................

    Every once in a while I take you guys off ignore just to expose you and to have a good laugh......

  • He lurks in the background following every word of every post of the stocks that he follows. Notice his attempts at belittling posters for their lack of market knowledge.

    Why does he scour the boards so attentively? Good question is it not? He neither follows nor mentions the science, management, or potential. He has no interest in RXI as a company, only as feeding grounds for hm and his miscreant associates.

    His goal is solely to capitalize on creating fear among investors. He is not at all interested in RXI, he is only interested in preying on weak hands.

    He is a very slippery stock manipulator.

    It makes him highly disliked by all but one poster who frequents here. But this does not prevent him from his mission; untruths and deceit. the very one thing he lacks, integrity.


  • Reply to

    James Skalko

    by avl.morax Jun 23, 2014 11:11 AM
    rmsacc rmsacc Jun 23, 2014 2:46 PM Flag

    You do enjoy talking down to people don't you. I suppose that's why nobody likes you, that is except for one perhaps.

    Looks like you just ask for me to expose you for the miscreant that you are. I shall post some of your more memorable comments when I get the time.

    See folks he goes crazy when I expose his motives. Criminals do not like attention....................Good luck all

  • Reply to

    Email from Tamara for RXII

    by biotechpicklist Jul 25, 2014 8:23 PM
    rmsacc rmsacc Jul 25, 2014 10:37 PM Flag

    bio, as always many thanks. Your input most valuable. GLTA

  • His direct quotes from previous responses to me ;

    1. quote: "altruism and to share ideas with fellow investors. How's that? Satiate your need to "know?"
    2. quote: "What if I said I like to translate thoughts into words and this is my canvas?"
    3. quote: " I am only here to help you."

    Personally I like #3.

    Good luck All

  • Mr. White joined Laidlaw & Company Ltd. in June 2012 with over 16 years of Wall Street healthcare analyst experience. Prior to Laidlaw, he was the Senior Med Tech Equity Analyst (sellside) at Murphy & Durieu, an investment bank and NYSE member founded in 1929. While at Murphy & Durieu, Mr. White was recognized by StarMine as one of the top medical device analysts for accuracy of earnings estimates. He was the Senior Healthcare Analyst (buyside) at Mitsubishi UFJ Trust and Management (MUFG) for 6 ½ years before his time at Murphy. Mr. White generated ideas and managed healthcare equity investments for many funds at Mitsubishi including the primary ex-Japan fund, which at its peak held over $16 billion in equity assets including over $1.3 billion in US Healthcare equity holdings for which Mr. White was responsible. Prior to Mitsubishi, Mr. White was a sell-side analyst for 7 years. Over almost five years, he worked on two (Major Pharmaceuticals and Managed Care) Institutional Investor ranked sell-side equity teams at Deutsche Bank Securities. Prior to Deutsche Bank, Mr. White worked as a sell-side healthcare analyst at Gerard, Klauer Mattison & Company (now BMO Capital Markets) and Fahnestock & Company (now Oppenheimer & Co.). Mr. White graduated from Manhattan College with a B.S. in Biology and attended Mount Sinai School of Medicine for 2 ½ years. He received an M.B.A. in Finance from Rensselaer Polytechnic Institute. Mr. White holds the following security industry licenses: Series 7, 63, 86 and 87.

  • Reply to

    hedgehog: "the big shot"

    by avl.morax Jul 10, 2014 2:01 PM
    rmsacc rmsacc Jul 10, 2014 2:31 PM Flag

    A legend in his own mind...........................

  • strong positive I'd say........good weekend All......................

  • RXI has gone through P1 and near end of P2 in under two years. Not sure how many are aware just how fast that is. Attributable to quickness of skin healing along with readily visible results. Quite a different scenario from most drug trials. Most would have taken 3-5 times as long.

    Credit to Cauwenbergh who chose to take on the task of heading RXI, knowing the nearer term potential. (mu guess here). We have yet to get updated on the scope of the platform this could produce. News will be soon. Just my thought this afternoon.....GLTA

  • The name of RXI's new patent granted just a couple weeks ago. A rewind refresher and follow up on golong's post from yesterday;

    This core patent, within RXi's intellectual property portfolio, is the foundation for RXI's self-delivering platform. The patent broadly protects RXi's sd‑rxRNA technology, which facilitates the delivery of RNAi compounds to tissues and cells of interest in the absence of a delivery vehicle. sd‑rxRNA oligonucleotides are designed for therapeutic use and have drug-like properties, such as high potency, target specificity, serum stability, reduced immune response activation, and efficient cellular uptake. This allows sd‑rxRNAs to achieve efficient cellular uptake and potent, long-lasting intracellular activity.

    "We are pleased to have our novel technology recognized by the United States Patent and Trademark Office," said Dr. Geert Cauwenbergh, President and CEO of RXi Pharmaceuticals. He added that, "This key patent is what differentiates RXi's technology platform from the competition. It provides us with a powerful advantage to deliver our RNAi compounds without delivery vehicles, which are commonly used with the other siRNcompounds in clinical development. The use of our proprietary sd‑rxRNA technology platform may lead to improved tolerability and thereby potentially broadening of the therapeutic window for these compounds."

    Yes hedge, cut and paste for dummies.....

  • We are this much closer to a report on the p2 trials. It is literally right around the corner.

    The very reason why most are all still here. This stock got shaken up pretty good these last few months, as all the theories suggested, Manipulation, lack of interest?, a $35m M/cap?, a traders haven?, whatever.........
    I continue long, the science and the expertise keeps my interest........Good weekend to All.

  • Reply to

    Nuttin but crickets

    by celltones Jul 12, 2014 10:27 PM
    rmsacc rmsacc Jul 13, 2014 8:03 AM Flag

    Brilliant comment, such depth of reasoning. How can we ever thank you?

  • Reply to

    To avimoron, "the idiot" stock basher....

    by rmsacc Jun 12, 2014 10:48 AM
    rmsacc rmsacc Jun 12, 2014 12:26 PM Flag

    Can't you paid stock bashers control your anger? This is a public forum hedhrlks. Screaming in capital letter yet, telling me to "shut my mouth", how childish.

  • rmsacc rmsacc Jul 27, 2014 9:12 AM Flag

    That 113M was pre reverse split. It now equates to just 3.7M shares. Why are you such a jerk avi, attempting to deceive people with half truths and lies? You'll get yours avi.....................

  • Would Dr. Frost have made a private placement of nearly $17M at the time of the RXI OPK asset transfer?

    And would he do same if he were not confident in Dr. Cauwenbergh and the science of RXI?

    You see All, Avi "the moron" thinks he is tricky. He attempts to discredit with half truths and deceit.

    There is only one problem; He's not very good at it.................GLA

  • Reply to

    Go ahead Winthorp Jefferson tell us all why

    by adamsribmarrow Aug 10, 2014 4:57 PM
    rmsacc rmsacc Aug 10, 2014 5:19 PM Flag

    I think I might be able to take a crack at you question adam. Dr. Cauwenbergh comes to RXI with a backlog of contact and a strong history of successes in dermatology. After a 20+ year history as head of J$J' worldwide skincare division along with a highly lucrative career as CEO of two recent biotechs leading to sales in the $B's.

    He elected to take the helm of RXI. Keeping in mind his worldwide associations and contacts in this field, No doubt the new science of RNAi was the motivation, ( through the groundbreaking work of Dr. Craig Mello, Nobel prize as founder of gene silencing), within a short time frame, RXI has proved that the science works.

    He is surrounded by talent. We are within a short wait of P2 results. His CFO capabilities are well proven. The backlog of IP and the self delivery technology, as well as the recent discoveries in eye disease, will be noticed soon.

    $ to last until 2016, Commitments of $20M from LPC., A CEO who insists on progressing on time and on budged, and the backing of Dr. Frost with a $17M placement this year, all lead me to believe that RXI has more than something in the making.........a brief outline. Happy to expand ............GLTA

  • rmsacc rmsacc Jun 24, 2014 5:23 PM Flag

    Most here do not trade in the stock of $40m market cap experimental biotech stocks hanna. Personally I think its crazy. There is no action here at present.

    I like the science, the expanded IP, and especially the management. I"m in for long term. I have a very good feeling that the good Doctor has something in store..................good luck All

  • Can't say I'm surprised, after all you are all idiot MM lackeys working for day wages. We don't hate you for it, Its your job. Its just a stinking job, if you know what I mean..................

12.95Aug 26 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.